Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06956300 · ClinicalTrials.gov registry record · NA
TMS for Cognitive Decline in Aging and Preclinical AD
A NA study of Cognitive Decline and Healthy Aging, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06956300: Recruiting NA study of Cognitive Decline and Healthy Aging, sponsored by Massachusetts General Hospital.
NCT06956300 is a NA study of Cognitive Decline and Healthy Aging that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 1,148-participant average among 61 other Cognitive Decline trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06956300, a NA study of Cognitive Decline and Healthy Aging, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical Alzheimer's disease. This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls cognition. Changes resulting from this stimulation will be measured with behavioral tests, as well as by taking brain images with Magnetic Resonance Imaging (MRI). Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.
Primary Outcome
This will be measured by ratings of grit on a 5-point scale using the Grit Scale (Duckworth, et al., 2007).
Conditions Studied
Interventions
- DEVICE Active rTMS
- DEVICE Sham rTMS
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2029-08-31 |
| Phase | NA |
What NCT06956300 shows while recruiting
NCT06956300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,148-participant average among 61 other Cognitive Decline trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Cognitive Decline appearing as the primary indexed condition, and to 2 interventions - of which Active rTMS is the first listed.
NCT06956300 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06956300 about?
NCT06956300 is a clinical study titled "TMS for Cognitive Decline in Aging and Preclinical AD". In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical Alzheimer's disease. This study will use a form of non-invasive brain stimulatio...
What is the current status of trial NCT06956300?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-04-07. Estimated completion is 2029-08-31.
What conditions does trial NCT06956300 study?
This clinical trial studies the following conditions: Cognitive Decline, Healthy Aging, Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease.
What interventions are being tested in trial NCT06956300?
The interventions under investigation include: Active rTMS (DEVICE), Sham rTMS (DEVICE).
Who is sponsoring clinical trial NCT06956300?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06956300 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Decline
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06956300's enrollment target sits among peer trials
80 46th of 61 higher than 16 of 61 other Cognitive Decline trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Decline trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
mPATH for Low-income Older Adults
RECRUITING · NA
-
MindWalk Intervention for Older South Asian Caregivers of People With Cognitive Disabilities (CD)
RECRUITING · NA
-
Preventing Cognitive Decline by Reducing BP Target Trial
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Exercise Adherence and Cognitive Decline: Phase 2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI